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KEY POINTS
 The preclinical and clinical development of the rotigotine transdermal system has estab-
lished it as an effective method for providing continuous delivery of a dopamine agonist
across the skin.
 Rotigotine may have clinical advantages compared with other agents.
 Pharmacokinetic analysis of the rotigotine transdermal system has shown stable plasma
levels of rotigotine over a time period of 24 hours.INTRODUCTION
The motor deficits associated with Parkinson’s disease (PD) result from the progres-
sive loss of dopaminergic neurons in the substantia nigra pars compacta.1,2 Dopami-
nergic replacement (levodopa) and dopaminergic stimulation (dopamine receptor
agonists) are consequently central to the treatment of the motor deficits that typify
PD.2–4 Levodopa is the gold standard for dopaminergic therapy in PD; however, its
long-term use is complicated by the development of motor complications including
dyskinesias and the end-of-dose deterioration known as wearing off.3,5,6 These motor
complications increase functional disability and severely affect patients’ quality of
life.7,8 Wearing-off effects are thought to indicate a shortening of the effectiveness
window for levodopa, as a result of the progressive loss of nigrostriatal dopamine.6
Although the pathogenesis is still not fully understood, preclinical and clinical findings
suggest that the development of levodopa-induced dyskinesias is related to its short
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WatersS38and altered basal ganglia output.9,10 Normal striatal dopamine receptor stimulation is
thought to be continuous; therefore, continuous, rather than pulsatile, dopaminergic
drug delivery, which is based on the tonic/phasic hypothesis of dopamine release,
may more closely mimic physiologic dopaminergic stimulation.10,11 This possibility
is supported by various animal studies (reviewed in detail by Jenner elsewhere in
this issue) in which continuous dopaminergic delivery has been shown to substantially
improve mobility and reduce the incidence of dyskinesias.12–15
The rotigotine transdermal system (Neupro) is a dopamine receptor agonist that is
delivered over a 24-hour period.16 It is approved for idiopathic PD and restless legs
syndrome (RLS) in the United States and European Union.
This article reviews the development of the rotigotine transdermal system for the
treatment of PD, and the clinical pharmacology of rotigotine. The results of several
phase III clinical studies have been published that support the efficacy of the rotigotine
patch for the treatment of early and advanced PD. However, this article focuses on the
development of the medication from a pharmacokinetic point of view. A detailed
review discussing the results of the clinical studies can be found in the article by Lyons
and Pahwa elsewhere in this issue.RESULTS OF PRECLINICAL STUDIES: THE PHARMACOLOGIC PROFILE OF ROTIGOTINE
Rotigotine: the Active Compound
Rotigotine is the (–)-enantiomer of the aminotetralin derivative, 2-(N-propyl-N-2-
thienylethylamino)-5-hydroxytetralin; (originally termed N-0437), and is structurally
similar to dopamine.17 Early preclinical in vitro binding studies and in vivo studies
investigating the anti-Parkinson’s potential of N-0437 were performed on the () enan-
tiomeric mixture of N-0437.18 However, it was found after separation of the enantio-
mers that the (1) and (–) enantiomers of N-0437 showed marked differences in their
pharmacologic action; although both have been shown to act as agonists in presyn-
aptic models of dopaminergic receptor activity (induction of hypomotility in mice),19
only the (–) enantiomer (–)-N-0437 was effective in postsynaptic models (rotation
in 6-hydroxydopamine-lesioned rats).19 Although administration of the (–) enantiomer
improved locomotor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-
lesioned primates, there was no activity following administration of the (1) enan-
tiomer.20,21 Preclinical studies such as these led to the development of the (–)
enantiomer of N-0437 (rotigotine) for the treatment of PD [which later was also used
under the code N-0923, whereas the (1) enantiomer was termed N-092422].
The Receptor Profile of Rotigotine
Dopamine receptor activity
The affinity and functional activities of rotigotine have been determined at a broad
range of cloned human receptors in vitro. Conventional binding assays have shown
that, of the dopamine receptors, rotigotine binds with the highest affinity to the D3
receptor (inhibition constant [Ki] value of 0.71 nM), whereas its affinity is approximately
20-fold weaker at the D2 receptor (Ki value 5 13.5 nM), and approximately 100-fold
weaker at the D1 receptor (Ki value of 83 nM). Rotigotine also binds to the D4 (Ki of
3.9 nM at D4.2, 5.9 nM at D4.7, 15 nM at D4.4) and D5 (Ki of 5.4 nM) receptors.
23 Func-
tional assays, measuring intrinsic activity, have confirmed that rotigotine behaves as a
potent agonist at all five dopamine receptors; its potency at the D3 and D2 receptors is
2600 and 53 times higher than that of dopamine, whereas it is similar to that of dopa-
mine at the D1 receptor.23 Activation of the D1 receptor is unique to rotigotine among
the non–ergot-derived dopamine receptor agonists; for example, pramipexole and
Rotigotine Transdermal Patch S39ropinirole have been shown to act at the D2 and D3 receptors, but exhibit little or no
affinity at the D1 receptor.24,25 The ergot-derived dopamine receptor agonist, pergo-
lide, does have D1 receptor properties,26 but is not widely available.
The dopamine receptor–binding and activation profile of rotigotine is clearly key to
its role in PD. The role of D3, D2, and D1 receptors in the control of normal motor
activity by dopamine, and their activation in the treatment of PD, are well recognized.27
Anatomic and neurochemical studies reveal that the D3 receptor is presynaptically
localized in the substantia nigra pars compacta and seems to play a role in modulating
dopamine release.28 The D2 receptor is abundant in the caudate-putamen of the
dorsal striatum; stimulation is thought to increase locomotion.28 The D1 receptor is
the most widespread dopamine receptor in the central nervous system and is highly
expressed in the striatum. Evidence suggests a synergistic interaction between D1
and D2 receptors29–31; in the MPTP-lesioned monkey model of PD, a high-efficacy
D1 receptor agonist acted synergistically with a D2 receptor agonist to prolong the
motor stimulation induced by each drug alone.31
Nondopamine receptor activity
Among nondopaminergic sites, rotigotine also binds to serotonergic 5-hydroxytrypta-
mine (5-HT)1A and alpha2B-adrenergic receptors, at concentrations similar to those at
the D1 and D2 receptors (Ki 5 30 nM and 27 nM).
17,20,23 Rotigotine acts as an agonist
at the 5-HT1A receptor, but as an antagonist at the alpha2B receptor,
17,23 and this may
also play a role in its efficacy profile.
Although PD is primarily a disorder of the nigrostriatal dopaminergic pathway,
dysfunction of nondopaminergic systems, including serotoninergic and norepinephri-
nergic pathways, may contribute to the development of both motor and nonmotor
symptoms.32–34 For example, depression is a common nonmotor symptom in patients
with PD and has been linked to low serotonin levels; imaging studies have reported
reduced 5-HT1A receptor binding in patients with major depressive disorders
compared with normal controls,35,36 and reductions in serotonin levels of approxi-
mately 50% have been reported in the cortex and basal ganglia of patients with
PD.32,34 Furthermore, alpha2-adrenoceptors located within the striatummaymodulate
gamma-aminobutyric acid–ergic function and contribute to the generation of dyskine-
sias in PD.34 Activation of 5-HT1A receptors and inhibition of alpha2-adrenergic recep-
tors have therefore been identified as potential therapeutic strategies for the treatment
of motor symptoms of PD as well as certain nonmotor symptoms, such as anxiety and
depression.34,37,38 In experimental studies, specific alpha-adrenergic receptor antag-
onists, when combined with levodopa, have been shown to reduce the incidence of
dyskinesias and prolong the antiparkinsonian effect of levodopa,39 whereas the
alpha2-adrenergic receptor antagonist mirtazapine, which also acts at several 5-HT
receptor subtypes, has been shown to improve depressive symptoms and sleep
parameters.40 Thus, agents that target the serotoninergic and norepinephrinergic
pathways, in addition to the classic dopaminergic system, may prove useful in the
treatment of PD.32
In Vivo Effects of Continuous Administration of Rotigotine
In rats, a single subcutaneous injection of the slow-release rotigotine preparation
resulted in a constant level of extracellular striatal rotigotine for up to 48 hours and
a concomitant sustained decrease in extracellular dopamine as measured using a
microdialysis probe inserted into the striatum.41 In 6-hydroxydopamine–lesioned
rats, Schmidt and colleagues42 (2008) showed that subcutaneous administration of
slow-release rotigotine nearly abolished the induction of dyskinetic movement
WatersS40compared with pulsatile administration of rotigotine (once-daily or twice-daily intra-
peritoneal injection) or pulsatile levodopa. In MPTP-lesioned marmosets, continuous
rotigotine infusion (delivered via osmotic pump) reduced the expression of dyskinesias
compared with pulsatile administration (Fig. 1).43 Although both continuous and pul-
satile administration of rotigotine improved motor deficits and normalized motor func-
tion, animals receiving pulsatile rotigotine eventually reverted to a parkinsonian state
during the trough of the plasma levels and were unresponsive to external stimuli during
that period. In contrast, animals receiving continuous rotigotine performed their
normal diurnal activities, and continued to remain responsive to external stimuli during
that period.43
Rotigotine Toxicology
The toxicology of rotigotine has been evaluated in several preclinical studies and
results are available in summary in the prescribing information for rotigotine44 and pre-
sented in detail in the marketing-authorization scientific discussion.45 To summarize,
retinal degeneration has been observed in a 3-month study of rats receiving rotigotine;
however, it has not been observed in routine histopathologic observation of other
species, and the relevance to humans is unknown. Moreover, the dose used in this
study was equivalent to 5.6 times the maximum human recommended dose.45 In
carcinogenicity studies in male and female rats receiving rotigotine, Leydig cell hyper-
plasia and testicular and uterine tumors were observed following administration of
medium to high doses; these tumor types are related to the well-known effect in
rats on decreased prolactin levels by dopamine agonists such as rotigotine. The accu-
mulated information of compounds in this class has led to the conclusion that rotigo-
tine does not seem to pose a carcinogenic risk for humans.44,45 At high doses,
rotigotine has been shown to reduce the motility of spermatozoa in male rats, but to
have no effect on fertility. However, fertility was reduced in female rats. The implication
of these effects for humans is not known.44,45 No clinically relevant changes in clinical
laboratory values, vital signs, physical examinations, or electrocardiogram results that
indicate toxicity have been reported in any of the human clinical studies conducted to
date.1,46–500
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Fig. 1. Continuous subcutaneous application of rotigotine resulted in increased duration of
locomotor activity, increased reversal of motor disability, and shorter duration of dyskine-
sias, compared with pulsatile rotigotine delivery in MPTP-lesioned marmosets. Black bars,
continuous subcutaneous application of rotigotine; white bars, pulsatile rotigotine delivery.
(Data from Stockwell KA, Scheller D, Rose S, et al. Continuous administration of rotigotine
to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces
dyskinesia induction. Exp Neurol 2009;219(2):533–42.)
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Rotigotine is highly lipid soluble, and therefore appropriate for transdermal administra-
tion,16 whereas oral formulations of rotigotine undergo extensive first-pass gastroin-
testinal (GI) metabolism.51,52 In a study in MPTP-lesioned marmosets, topical
application of an alcohol-based rotigotine solution improved locomotor activity for
up to 48 hours, whereas the duration of action of the intraperitoneal and oral formula-
tions was approximately 2 hours.21 Thus, these data support the administration of
rotigotine via the transdermal route. The transdermal delivery system consists of a
thin, silicone-based, matrix-type patch composed of 3 layers (Fig. 2) as follows:
 A flexible backing film that provides structural support and protects the drug-
loaded layer from the environment
 A self-adhesive drug matrix layer that contains the active component rotigotine
and inactive components
 A transparent polymer liner that protects the adhesive layer during storage and is
removed before application.44
Rotigotine drug delivery has been shown to be proportional to patch size. Hence,
increasing the surface area of the patch allows the dose to be increased. For the treat-
ment of PD, patches are available in several sizes: 10 cm2, 20 cm2, 30 cm2, and
40 cm2; it has been estimated that the release of rotigotine from the patch is
0.2 mg/cm2 over a 24-hour period. Thus, the apparent dosage of rotigotine ranges
from 2 mg/24 h for a 10-cm2 patch containing 4.5 mg to 8 mg/24 h for a 40-cm2 patch
containing 18 mg.44
RESULTS OF PRELIMINARY CLINICAL STUDIES
Proof-of-concept Studies of Rotigotine in Patients with PD
Preliminary clinical studies of early formulations of rotigotine in patients with PD sug-
gested that rotigotine was efficacious for the treatment of the motor symptoms of PD.
Continuous intravenous infusion of rotigotine over 4.5 hours to 9 patients with moder-
ate to severe PD showed antiparkinsonian effects, as measured by a modified
Columbia scale.53 In a 3-week, phase II, placebo-controlled, dose-finding trial of an
early patch formulation of rotigotine in 85 patients with PD, administration of the
2 highest doses of rotigotine enabled the levodopa dose to be reduced (primary
outcome).54 In a 4-week study of 7 patients with advanced PD and on/off fluctuationsFig. 2. The transdermal rotigotine patch. (Courtesy of UCB Pharma SA, Brussels, Belgium;
with permission.)
WatersS42and dyskinesias, transdermal administration of rotigotine allowed a reduction in levo-
dopa dose without loss of antiparkinsonian efficacy. Moreover, there was a dose-
response relationship between rotigotine dose and the reduction in levodopa, and
most patients experienced less off time and more on time without dyskinesia.55 In
these preliminary studies, rotigotine was also well tolerated.53–55 Based on these
favorable preliminary findings, studies to evaluate the metabolism and disposition of
rotigotine were undertaken.
Rotigotine Metabolism
The metabolism of rotigotine has been investigated in vitro in rat, monkey, and human
liver microsomes, and perfused rat livers, and in vivo in healthy humans.56–60 These
studies show that rotigotine is extensively metabolized in vivo, with the major route
being conjugation of the parent compound by sulfation. A further metabolic pathway is
through cytochrome P450 (CYP)–dependent N-dealkylation to N-despropyl-rotigotine
andN-desthienylethyl-rotigotine, which are, in turn, subsequently conjugated with sul-
fate or glucoronide.56,58 The main metabolites of rotigotine are thought to have little
pharmacologic activity because plasma concentrations are more than 10 times lower
than that of the parent compound.56 Preclinical studies show that multiple CYP
isoforms are able to metabolize rotigotine, suggesting that no specific CYP isoform
acts as a rate-limiting factor for rotigotine metabolism.58 This is relevant when consid-
ering potential drug-drug interactions, as discussed later in this article.
Rotigotine metabolites are predominantly excreted by the kidneys (w71% in urine)
with w23% excreted via the feces, which corresponds with a renal clearance of
12.3 L/h and fecal clearance of 4.0 L/h (Fig. 3). Less than 1% of the parent rotigotine
compound is excreted unchanged in the urine.56 Transdermal delivery of rotigotine is
unaffected by food, gastric emptying or impaired gastric motility, or first-pass
metabolism.61,62
Steady-state Pharmacokinetics of Rotigotine
In vitro studies conducted on excised human skin have shown linear drug permeation
of rotigotine over the intended application time of 24 hours with the rotigotine patch.63
Approximately 95% of the rotigotine in a 10-cm2 patch (containing 4.5 mg rotigotine) is
recovered within 96 hours of patch application, inclusive of the residual rotigotine in0
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Fig. 3. Most radiolabeled rotigotine is excreted by the kidneys. (From Cawello W, Wolff HM,
Meuling WJ, et al. Transdermal administration of radiolabelled [14C]rotigotine by a patch
formulation: a mass balance trial. Clin Pharm 2007;46(10):851–7; with permission.)
Rotigotine Transdermal Patch S43the patch.57 In healthy volunteers or patients with early-stage PD, once-daily applica-
tion of the rotigotine patch provided stable, dose-dependent, steady-state plasma
concentrations over the 24-hour patch application period.64,65 Moreover, mean
plasma concentrations of rotigotine were similar for different patch application sites.64
The absolute bioavailability of rotigotine after patch application is approximately 37%
to 46% of the applied dose (>60% of the drug delivered to the skin).56,57 Rotigotine
plasma concentrations increase over time, reaching maximum levels between 12
and 24 hours after first patch application in healthy human subjects,56,57 and they
decrease quickly, with an elimination half-life of 5.3 hours, after patch removal.56 A
slight transient dip in mean rotigotine plasma concentrations has been observed
over the 1 to 4 hours following the application of a new patch,66 but this is consistent
with a lag time for absorption with a new patch. Overall, plasma levels of rotigotine
generally remain stable throughout long-term treatment.47,66 It is thought that the
negligible changes during periods of patch removal and replacement are unlikely to
have any clinically relevant impact on motor performance.
Drug-drug Interactions with Rotigotine
Drug metabolism via the CYP system is a key source of drug interactions that can
result in drug toxicity, reduced efficacy, or an increase in side effects. However, as
noted previously, multiple pathways and CYP isoforms seem to be capable of metab-
olizing rotigotine; thus, if one pathway is inhibited, others can continue to metabolize
the drug.58 In vitro studies with human CYP enzymes have shown that selective inhi-
bition of these CYP isoforms fails to inhibit rotigotine metabolism.58 Moreover, subcu-
taneous rotigotine administration did not significantly affect CYP enzyme activity in
cynomolgus monkeys.58 Hence, rotigotine can be expected to have a low risk of
drug-drug interactions. Coadministration of rotigotine with domperidone, a dopamine
receptor antagonist that undergoes extensive CYP enzymatic metabolism and that is
commonly used as an antiemetic in patients treated with levodopa or dopamine ago-
nists, did not change the pharmacokinetic profile or renal elimination of rotigotine in
healthy subjects.67 These data suggest that rotigotine has a low risk of clinically rele-
vant drug-drug interactions related to CYP-450 metabolism. Moreover, in patients
with RLS, the mean concentration-time profiles of rotigotine, levodopa, and carbidopa
were similar during monotherapy and combination therapy, suggesting a lack of
pharmacokinetic interactions between these compounds.68 However, as would be
expected, rotigotine may potentiate the adverse effects of levodopa.44,69
Pharmacokinetics of Rotigotine in Special Populations
Because the prevalence of PD increases with age, the effects of impaired hepatic or
renal function on the pharmacokinetics of PD drugs must be considered. The pharma-
cokinetics of rotigotine are similar regardless of age (<65 years and 65 years) or
gender in patients with early-stage PD,64 and are similar in healthy Japanese andwhite
subjects administered a single rotigotine transdermal patch.70 Moreover, moderate
hepatic impairment (Child-Pugh class B) does not seem to affect rotigotine pharmaco-
kinetics or the renal clearance of unconjugated rotigotine following repeated patch
application.71 In addition, no differences in bioavailability or total clearance of rotigo-
tine were observed between healthy subjects and symptomatic volunteers with mild to
severe chronic renal insufficiency and those requiring hemodialysis72; mean plasma
concentration-time curves of unconjugated rotigotine and the incidence of adverse
events were similar between groups.72 Taken together, these results suggest that
adjustments of rotigotine dose are not required for patients with moderate hepatic
impairment or chronic renal insufficiency.
WatersS44BENEFITS OF TRANSDERMAL DELIVERY VERSUS ORAL ADMINISTRATION
Transdermal administration may be more pharmacologically effective than oral admin-
istration for patients with PD. Transdermal administration provides continuous delivery
of medication, resulting in constant plasma levels, and therefore avoids the plasma
level peaks and troughs associated with more pulsatile oral drug delivery. Moreover,
it enables controlled drug delivery over longer periods of time than with oral adminis-
tration, and administration can be readily discontinued by patch removal.62,73 It may
improve patient compliance, particularly in patients already receiving multiple oral
medications or in patients who may have difficulty swallowing.74 Transdermal delivery
also avoids hepatic first-pass metabolism and the GI tract. GI disorders, including
difficulty swallowing and delayed gastric emptying, are the most commonly observed
nonmotor symptoms of PD; the results from a retrospective claims database analysis
suggest that around 65% of patients with PD have a GI disorder 4 years after diag-
nosis of PD.75 Delayed gastric emptying results in increased retention in the stomach,
which, in turn, leads to inconsistent intestinal absorption of orally delivered medica-
tion. Thus transdermal drug delivery may be preferable to oral administration in
patients with PD with altered gastric emptying and other GI disorders.
A retrospective cohort study has shown that patients with PD have significantly
longer acute hospital stays and significantly higher in-hospital mortality than individ-
uals without the disease.76 Because oral PD medications often require multiple doses
throughout the day, many patients with PD undergoing surgical procedures likely miss
one or more doses of medication. Thus, the management of PD symptoms in surgical
patients is commonly problematic. Issues include postoperative confusion, worsening
of PD, off symptoms, and parkinsonism-hyperpyrexia following sudden withdrawal of
dopaminergic medication.77–79 Transdermal delivery of rotigotine may be of particular
value in patients undergoing surgery by potentially reducing the complications asso-
ciated with disruption of regular medication dosing schedules.79,80 In one study, the
oral PD medications (levodopa, pramipexole, ropinirole, amantadine, catechol-O-
methyl transferase (COMT) inhibitors, rasagiline, and biperidine) of 14 patients with
PD receiving general anesthesia79 were switched to transdermal rotigotine the eve-
ning before surgery, with most patients (64.3%) able to switch from rotigotine back
to prior PD medications within 24 hours following the surgery. Based on a feasibility
questionnaire, nearly all neurologists and anesthesiologists (89% for both), and
100% of patients, completely agreed (rating of 1) or agreed (rating of 2) that the trans-
dermal rotigotine patch was an easily feasible option for managing perioperative PD
symptoms. Of the neurologists, 7 of 9 (78%) completely agreed (rating of 1) that no
unexpected perioperative PD symptoms occurred. These findings are consistent
with those of an earlier case study80 in which no perioperative worsening of symptoms
was noted for 25 patients with PD who had undergone a surgical procedure unrelated
to PD and had received rotigotine. A non–clinically important difference of 0.4 (3.08)
points was found between the preoperative and postoperative Unified Parkinson’s
Disease Rating Scale (UPDRS) part III score, signifying sustained control of parkinso-
nian symptoms (a difference of 2.3–2.7 points reflects a minimal clinically important
difference on UPDRS part III81).
RESOLVING TRANSDERMAL ROTIGOTINE CRYSTALLIZATION
The formation of rotigotine crystals in the transdermal patch led to the product being
withdrawn from the US market in 2008 because of concerns as to the impact on the
bioavailability of rotigotine and the subsequent effects on efficacy. The crystallization
is caused by the formation of a more stable and less soluble polymorph of pure
Rotigotine Transdermal Patch S45rotigotine within the patch. Because only free molecules of rotigotine can cross into
the skin, the crystals need to dissolve for rotigotine molecules to be absorbed.82 Modi-
fication of the production process to inhibit the formation of crystals and implementa-
tion of a cold chain storage and distribution system in which the patches are
refrigerated from the manufacturer to the patient have alleviated these concerns in
Europe.82 However, in the United States, the US Food and Drug Administration
(FDA) requested an alternative approach to the cold chain solution, which has led to
the development of a novel room-temperature formulation of the rotigotine trans-
dermal patch. The bioavailability of this newer room-temperature formulation is
consistent with the previous formulation of the rotigotine patch, thus satisfying the
FDA requirements.83
SUMMARY
The rotigotine transdermal system provides a continuous mode of delivery, and a
convenient once-a-day, nonoral option for treating the signs and symptoms of PD.
It is hoped that continuous delivery provides a more physiologic option for treating
PD. Pharmacokinetic analysis of the rotigotine transdermal system has shown stable
plasma levels of rotigotine within the intended application time of 24 hours, with negli-
gible variation in the periods between patch removal and replacement. Rotigotine has
a low risk of drug-drug interactions because its metabolism is independent of a single
CYP-450 enzymatic pathway, and dosing adjustments are not required in patients
with hepatic or renal insufficiency. Its perioperative use in patients with PD who are
undergoing surgical procedures represents a particular advantage for its transdermal
mode of delivery.
In conclusion, the preclinical and clinical development of the rotigotine transdermal
system has established this system as an effective method for providing continuous
delivery of a dopamine agonist across the skin, and may have clinical advantages
compared with other agents.
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